(Q30451303)

21 June 2017

1 reference

title

Safety of stimulant treatment in attention deficit hyperactivity disorder: part II. (English)

1 reference

attention deficit hyperactivity disorder

21 June 2017

1 reference

0 references

author name string

Richard Lawrence Merkel

series ordinal

1

1 reference

21 June 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

Expert Opinion on Drug Safety

21 June 2017

published in

1 reference

21 June 2017

volume

9

1 reference

21 June 2017

issue

6

1 reference

21 June 2017

page(s)

917-935

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

21 June 2017

1 reference

Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Long-term safety of stimulant medications used to treat children with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

21 January 2018

Stimulant medications

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Depression and psychotic regression following prolonged methylphenidate use and withdrawal: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Frontiers between attention deficit hyperactivity disorder and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Psychotic side effects of psychostimulants: a 5-year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Attention deficit hyperactivity disorder and suicide: a review of possible associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Methylphenidate euphoria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Abuse of Prescribed Stimulant Medication by a 13-Year-Old Hyperactive Boy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Attention deficit/hyperactivity disorder across the lifespan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Naturalistic long-term use of methylphenidate in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

An open study of methylphenidate in bipolar depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Safety and tolerability of methylphenidate in preschool children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

A conceptual review of the comorbidity of attention-deficit/hyperactivity disorder and anxiety: implications for future research and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Nature of anxiety comorbid with attention deficit hyperactivity disorder in children from a pediatric primary care setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

ADHD with comorbid anxiety: a review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Effect of anxiety on cognition, behavior, and stimulant response in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

When attention-deficit/hyperactivity disorder co-occurs with anxiety disorders: effects on treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Response of children with ADHD to methylphenidate: interaction with internalizing symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

ADHD comorbidity findings from the MTA study: comparing comorbid subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Anxiety and depression symptoms and response to methylphenidate in children with attention-deficit hyperactivity disorder and tic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Obsessive-compulsive symptoms following stimulants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Methylphenidate-induced obsessive-compulsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Dexamphetamine for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Stimulant use and trichotillomania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Adderall for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

The ADHD and sleep conundrum: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Methamphetamine induces chronic corticostriatal depression: too much of a bad thing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Optimizing therapy of seizures in children and adolescents with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Use of Methylphenidate for Attention-Deficit Hyperactivity Disorder in Patients With Epilepsy or Electroencephalographic Abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Stimulant therapy and seizure risk in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Methylphenidate to treat ADHD is not contraindicated in children with tics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Methamphetamine and cardiovascular pathology: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Sudden death and use of stimulant medications in youths.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Long-term treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Growth and sexual maturation in children and adolescents with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Hospitalizations with amphetamine abuse among pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Methamphetamine detection in maternal and neonatal hair: implications for fetal safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Cytogenetic effects in children treated with methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Brief review of available evidence concerning the potential induction of genomic damage by methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Use of methylphenidate in a patient with glaucoma and attention-deficit hyperactivity disorder: a clinical dilemma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Stimulant rebound: how common is it and what does it mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Rebound effects with long-acting amphetamine or methylphenidate stimulant medication preparations among adolescent male drivers with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Methylphenidate and growth in hyperactive children. A controlled withdrawal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Spotlight on methylphenidate controlled-delivery capsules (Equasym XL, Metadate CD) in the treatment of children and adolescents with attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Pemoline hepatotoxicity and postmarketing surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Methylphenidate-induced autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Methylphenidate and dextroamphetamine-induced peripheral vasculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

3-Year Follow-up of the NIMH MTA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Unravelling sleep problems in treated and untreated children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Quantitative Brain Magnetic Resonance Imaging in Attention-Deficit Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

Characteristics of Parent- and Child-Reported Anxiety in Psychostimulant Medication Naïve, Clinically Referred Children with Attention Deficit Hyperactivity Disorder, Combined Type (ADHD-CT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.503238

10.1517/14740338.2010.503238

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference